Cerus Corporation
Cerus Corporation develops and commercializes the INTERCEPT Blood System to enhance blood safety. The company offers systems for platelets, plasma, and red blood cells to reduce blood-borne pathogens. Its products are sold through a direct sales force and distributors globally. Cerus also produces pathogen-reduced cryoprecipitated fibrinogen complex and plasma. The company was incorporated in 1991 and is headquartered in California.
Overview
Strengths
- Pricing power: gross margin has held between 51% and 55% over the last 6 years (latest 54.5%).
- Consistent growth: revenue has compounded at 17.5% a year over 5 years, rising in 4 of them.
- Paying down debt: long-term debt fell by 14.0 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 3.3%) has been below its cost of capital of 10.1% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 4 of the last 6 years.
- Unstable profitability: operating margin ranged from -63% to -4% over the last 6 years, with operating losses in 6 of them.
Key Financial Data